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Available online xxxxThe Gaucher Outcome Survey (GOS) is an international disease-speciﬁc registry established in 2010 for patients
with a conﬁrmed diagnosis of Gaucher disease (GD), regardless of GD type or treatment status. For insight into
how GD management varies among countries, we analyzed treatment patterns in GOS. As of October 30, 2015,
data on GD-speciﬁc treatment (enzyme replacement therapy, substrate reduction therapy, or chemical chaper-
one therapy) received at any time were available for 647 patients. At analysis, velaglucerase alfa (316/573,
55.1%) and imiglucerase (184/573, 32.1%) were the treatments most widely used. Of the 647 treated patients,
446 (68.9%) had been treated for N5 years and 368 (56.9%) had received only one GD-speciﬁc drug therapy.
There were 377 patients who received velaglucerase alfa. Velaglucerase alfa was most widely used at 60 U/kg
every other week (134/492 dose entries, 27.2%), but there were differences in dosing between the three
highest-enrolling countries (deﬁned as N100 GOS patients enrolled in each), with most patients in Israel receiv-
ing b20 U/kg, most patients in the United Kingdom receiving 20 to b40 U/kg, and most in the United States re-
ceiving 60 U/kg. This analysis provides a foundation upon which to examine real-life outcomes data from
different treatment regimens globally.
© 2016 Published by Elsevier Inc.Keywords:
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Patients with Gaucher disease (GD) have a genetic deﬁciency in the
lysosomal enzyme β-glucocerebrosidase. The consequent accumulation
of glucosylceramide and other substrates is responsible for disease
manifestations, although the exact diseasemechanisms remain obscure
[1]. The disease is progressive, but age at symptom onset and clinical
course are highly variable among patients.
Decisions regarding GD management may be complicated by the
clinically heterogeneous nature of the disease and patients' varied re-
sponses to treatment. Therapeutic regimens need to be tailored toGaucher disease; GOS, Gaucher
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ood Cells Mol. Diseases (2016individual patients [2]. In 2004, a panel of GD experts published a series
of therapeutic goals to assist in treatment decision-making [3]. These
goals were based on clinical experience with imiglucerase, but new
treatment options have become available since their publication. Treat-
ment decisions may be further inﬂuenced by country-level directives,
insurance or reimbursement issues, patient-speciﬁcmedical contraindi-
cations, patient preference, and physicians' previous experience.
Six products have been approved for the treatment of GD: four en-
zyme replacement therapies (ERTs) and two substrate reduction thera-
pies (SRTs). ERT is the standard of care for treating symptomatic type 1
GDpatients and is effective for treating diseasemanifestations including
anemia, thrombocytopenia, hepatosplenomegaly, and GD-related bone
disease [4,5]. The ERT alglucerase ﬁrst receivedmarketing authorization
in 1991 andwas subsequently replaced by the recombinant enzyme im-
iglucerase, which received authorization in 1994 [6]. Velaglucerase alfa,
the human cell line derived ERT, was approved in 2010 [7] and
taliglucerase alfa in 2012 (commercial availability of these treatments
varies by country; see Supplementary Table 1 for marketing authoriza-
tion dates of available GD-speciﬁc treatments in the United States, the
European Union, and Israel) [8].), http://dx.doi.org/10.1016/j.bcmd.2016.10.014
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tion plant resulted in a supply shortage of the drug, which caused signif-
icant treatment interruptions or dose reductions for patients worldwide
[6]. The imiglucerase shortage stimulated a number of compassionate
use and early access programs in many countries that granted patients
pre-approval access to velaglucerase alfa and taliglucerase alfa [9,10].
The SRTmiglustat, which inhibits the enzyme glucosylceramide syn-
thase to reduce accumulation of glucosylceramide, ﬁrst received mar-
keting authorization in 2003 [11]. A second SRT, eliglustat, was
approved in 2014 (Supplementary Table 1) [12]. Miglustat can amelio-
rate disease manifestations but is only indicated in patients with type 1
GD for whom ERT is unsuitable (Europe) [13] or not a therapeutic op-
tion (United States) [14]. Eliglustat has shown efﬁcacy on disease pa-
rameters with an acceptable safety proﬁle, and is approved in the
European Union and the United States as a ﬁrst-line therapy for adults
with type 1 GD [15,16].
Pharmacological chaperones,whichmay assist folding of themutant
β-glucocerebrosidase to enable its correct trafﬁcking to the lysosome,
have been investigated as therapeutic options for GD. In particular,
ambroxol has been shown to increase the lysosomal activity of some
mutant β-glucocerebrosidases, although clinical response in patients
who received ambroxol in a pilot study was varied [17,18].
Analysis of real-world treatment patterns can provide a picture of
how GD management varies among countries, and can serve as a foun-
dation for analyzing clinical outcomes data to assess the effectiveness of
different therapeutic approaches globally.
The Gaucher Outcome Survey (GOS) is an international GD-speciﬁc
registry established in 2010 for patients with a conﬁrmed GD diagnosis,
regardless of GD type or treatment status. GOS collects real-world data
from GD patients, including information on disease manifestations
and treatment history. As of October 2015, 34 treatment centers special-
izing in the management of GD and other lysosomal storage diseases in
10 countries have participated in GOS, generating data on 1003 patients.
GOS is governed by GD experts from participating sites who, among
other responsibilities, provide input into the GOS protocol and advice
on data collection and analysis. The objectives of the registry include
to evaluate the safety and long-term effectiveness of velaglucerase
alfa, to characterize patients receiving velaglucerase alfa or other GD-
speciﬁc treatments, to gain a better understanding of the natural history
of GD and to serve as a database for evidence-basedmanagement of GD.Patients in
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level differences.
2. Patients and methods
2.1. Patients
GOS is an ongoing GD registry with participating sites in Israel, the
United States, the United Kingdom, Argentina, Brazil, Paraguay, Russia,
France, Italy, and Spain at the time of analysis. Patients can be enrolled
into GOS regardless of their treatment status or type of treatment re-
ceived. For enrollment, patients must have a diagnosis of GD conﬁrmed
by biochemical analysis of glucocerebrosidase activity and/or by GBA1
genotyping. Patients enrolled in ongoing blinded clinical trials cannot
be enrolled in GOS.
Patients in this analysis were enrolled into GOS on a voluntary basis
at the discretion of the physician and the patient and were managed
under the direction of their physician in accordancewith routine clinical
practice. Written informed consent was obtained from all patients.
2.2. Data collection
All data were collected via theweb-based GOS electronic case report
form. For patients who had received any GD-speciﬁc treatment at any
time (at any point before or after their enrollment into GOS), informa-
tion on each GD-speciﬁc treatment regimen received was collected, in-
cluding the drug name, treatment dose, frequency of administration,
and start and stop dates. GD-speciﬁc treatments were deﬁned as all
ERTs (alglucerase, imiglucerase, velaglucerase alfa, taliglucerase alfa)
and SRTs (miglustat, eliglustat), and the pharmacological chaperone
ambroxol.
2.3. Analysis
Analysis was conducted on data extracted from the database on
October 30, 2015. “Untreated” patients refers to those for whom
there was an indication of not having received GD therapy and no re-
cords of GD-speciﬁc treatment at any time. “Treated” patients refers
to those for whom there were one or more records of a GD-speciﬁc
treatment and a treatment start date speciﬁed (Fig. 1.) Patients not GOS
3 
ed”
1 
e information
treated
3 
Patients missing information
on treatment status
n = 155 
Patients missing full
information on being treated
n = 48 
Patients missing full
information on being untreated
n = 2 
Total patients with missing
information
n = 205 
atients,n=1003). “Untreated”patients refers to those forwhom therewas an indication of
atients refers to those forwhomtherewere one ormore records of a GD-speciﬁc treatment
reatment status were excluded from the analysis (gray boxes).
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were classiﬁed as having missing information and were excluded
from the analysis.
Data on GD-speciﬁc treatment status and duration of treatment ex-
posure were analyzed overall and by country. Information on numbers
of treated patients and treatments received were analyzed overall, by
country, and by age group (b18 and ≥18 years of age). Sequences of
treatment were analyzed overall for patients who switched from one
treatment to another. For patients who received velaglucerase alfa,
data on dose and frequency of administration were analyzed overall,
by country, and by age group.3. Results
3.1. Treatment status
Information on GD-speciﬁc treatment received at any time (any
ERT, SRT, or ambroxol) is available in GOS for 647 patients
(Table 1). There are 151 patients reported as having never receivedTable 1
Demographics of treated and untreated patients at time of entry into GOS (n= 798).
Treated patients,
n (%)a (n = 647)b
Untreated patients,
n (%) (n = 151)
b18 years
(n= 78)
≥18 years
(n= 569)
b18 years
(n= 21)
≥18 years
(n= 130)
Sex
Male 44 (56.4) 248 (43.6) 13 (61.9) 58 (44.6)
Female 34 (43.6) 321 (56.4) 8 (38.1) 72 (55.4)
Ethnicity
Ashkenazi Jewish 20 (25.6) 338 (65.0) 20 (95.2) 120 (93.8)
Other 58 (74.4) 182 (35.0) 1 (4.8) 8 (6.3)
Missing information 0 49 0 2
GD type
1 62 (80.5) 559 (98.8) 21
(100.0)
129 (99.2)
2 1 (1.3)c 0d 0 0
3 14 (18.2) 7 (1.2) 0 1 (0.8)
Missing information 1 3 0 0
GBA1mutation alleles
[c.1226ANG] + [c.1226ANG]
(N370S/N370S)
2 (3.3) 160 (39.2) 10 (76.9) 85 (76.6)
[c.1226ANG] + [c.1448TNC]
(N370S/L444P)
9 (14.8) 53 (13.0) 0 2 (1.8)
[c.1226ANG] + [c.84dupG]
(N370S/84GG)
8 (13.1) 44 (10.8) 0 3 (2.7)
[c.1226ANG] + other
(N370S/other)
11 (18.0) 86 (21.1) 2 (15.4) 17 (15.3)
[c.1226ANG] + unknown
(N370S/unknown)
0 16 (3.9) 0 2 (1.8)
[c.1448TNC + [c.1448TNC]
(L444P/L444P)
8 (13.1) 4 (1.0) 0 0
[c.1448TNC] + other
(L444P/other)
2 (3.3) 0 1 (7.7) 1 (0.9)
Other/other 21 (34.4) 45 (11.0) 0 1 (0.9)
Missing information 17 161 8 19
Splenectomy status
Non-splenectomized 77 (98.7) 413 (72.6) 21 (100) 122 (93.8)
Splenectomized 1 (1.3) 156 (27.4) 0 8 (6.2)
ERT, enzyme replacement therapy; GD, Gaucher disease; GOS, Gaucher Outcome Survey;
SRT, substrate reduction therapy.
a All percentages in table determined from number of patients with available data.
b Patients in GOS who had received GD-speciﬁc treatment at any time (any ERT, SRT,
and/or ambroxol).
c Patient's GD type is being conﬁrmed as it is unlikely that a patient with type 2 GD
would have been receiving treatment.
d One patient in the registry ≥18years of agewas recorded as having type2GD. Because
type 2 GD patients rarely survive beyond 2–3 years of age, this patient is included under
‘missing information’ while investigations into the patient's GD type are ongoing.
Please cite this article as: P. Deegan, et al., Blood Cells Mol. Diseases (2016treatment. Information on treatment status or treatment start date
is missing for 205 patients, who were excluded from the analysis
(Fig. 1).
At the time of analysis, three countries had enrolled N100 patients
into GOS. Israel had enrolled the largest number of patients (n =
460), followed by the United States (n=344) and the United Kingdom
(n = 108). Israel contributed the largest number of treated patients
(n = 301) and untreated patients (n = 140) to GOS (Fig. 2). Nearly
one-third of Israeli patients in GOS were untreated (140/460, 30.4%).
The majority of patients who had received treatment at any time
were ≥18 years of age (569/647, 87.9%; Table 1). Across both age
groups, more than two-thirds of patients had been treated for
N5 years (446/647, 68.9%; Supplementary Fig. 1).
There were 165 patients who had been splenectomized, of whom
157 (95.2%) had receivedGD treatment, whereas only 8 (4.8%)were un-
treated (Table 1).
In the untreated population, all patients were reported as type 1 GD,
except for one patient reported as type 3 GD. For untreated patients
with available GBA1 genotype data, the majority were [c.1226AN-
G] + [c.1226ANG] (N370S/N370S; 95/124, 76.6%), while patients with
this genotype accounted for just over one-third of treated patients
(162/469, 34.5%; Table 1). For the 64 patients with genotype [c.1226A-
G] + [c.1448TNC] (N370S/L444P), 62 (96.9%) were treated, and 2
(3.1%) were untreated. For the 55 patients with genotype [c.1226AN-
G] + [c.84dupG] (N370S/84GG), 52 (94.5%) were treated, and 3
(5.5%) were untreated.
The proportion of N370S/N370S patients varied between the three
highest-enrolling countries. In Israel, 227 of 389 (58.4%) patients with
genotype data were N370S/N370S, compared with 46 of 176 (26.1%)
patients in the United States and 3 of 51 (5.9%) patients in the United
Kingdom (Fig. 3).
3.2. GD-speciﬁc treatment patterns
At the time of analysis, 573 patients were receiving GD-speciﬁc
treatment, with the majority receiving velaglucerase alfa (316/573,
55.1%) or imiglucerase (184/573, 32.1%; Fig. 4). Patients in the United
States received the broadest range of treatments (six different treat-
ments). Only one patient b18 years of age was receiving SRT
(eliglustat); all others were receiving ERT (Supplementary Fig. 2).
An examination of the duration of exposure to individual treatments
over 5-year periods showed that most velaglucerase alfa patients had
received the drug for ≤5 years (227/377, 60.2%; Supplementary Fig. 3).
Imiglucerase had also been received most commonly for ≤5 years
(116/425, 27.3%), but there were comparable numbers of patients
who had received the drug for between 5 and 10 years (95/425,
22.4%), 10 and 15 years (97/425, 22.8%), and 15 and 20 years (84/425,
19.8%).
Of the 647 patients treated at any time, 368 (56.9%) had received
only one type of GD-speciﬁc treatment. The remaining patients (279/
647, 43.1%) changed treatments once or more, with the most common
switch being from imiglucerase to velaglucerase alfa (114/279, 40.9%;
Supplementary Fig. 4). There were 199 patients who switched to
velaglucerase alfa from other treatments and only 22 patients who
switched away to another treatment after having received
velaglucerase alfa. For the 13 patients who provided a reason for
switching away from velaglucerase alfa, the reasons were patient or
parent decision (n= 5), physician decision (n= 2), an insufﬁcient ef-
fect on disease parameters (n=2), pregnancy, reimbursement or insur-
ance issues, weight change, and experiencing an adverse event (n= 1
each).
3.3. Velaglucerase alfa treatment
There were 377 patients who had received at least one dose of
velaglucerase alfa at any time. Velaglucerase alfa was administered), http://dx.doi.org/10.1016/j.bcmd.2016.10.014
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Fig. 2. Treatment status by country (all GOS patients, n= 1003). Information on GD treatment received at any time (including prior to GOS entry) is available for 647 patients. There are
151 patients reported as having never received treatment. Israel contributes the highest number of treated and untreated patients to GOS. GD, Gaucher disease; GOS, Gaucher Outcome
Survey.
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treatment regimen was 60 U/kg every other week (134/492 dose
entries, 27.2%), followed by b20 U/kg every other week (117/492,
23.8%).
Differences were apparent among countries in the dosing of
velaglucerase alfa, with most patients in Israel receiving b20 U/kg,
most in the United Kingdom receiving 20 to b40 U/kg and most in
the United States receiving 60 U/kg (Fig. 5B). Of the 117 patients
who received b20 U/kg, 111 were from Israel (94.9%) and 6 were
from the United Kingdom; 116 of the 117 patients were ≥18 years
of age (Fig. 5).
4. Discussion
The clinical management of GD has changed considerably over
recent decades. Before the availability of ERT in 1991, management
focused on symptom relief (such as splenectomy) for patients with
severe disease. The cohort of patients treated in the early 1990s
often had a greater burden of disease. With the increased use of
ERT over time, symptomatic patients began to receive treatment at
younger ages and less severe stages of presentation [19]. Although
SRT was introduced in 2002, ERT has remained the gold standard of
treatment for GD, and for many years alglucerase and its successor
imiglucerase were the only enzyme products available to treat pa-
tients worldwide.
The 2009 shortage of imiglucerase had a profound impact on the
treatment of GD globally, and highlighted the need for alternative
GD-speciﬁc treatments. In response to the shortage, the manufactur-
ing timelines for velaglucerase alfa were accelerated and many pa-
tients began receiving velaglucerase alfa and taliglucerase alfa
before marketing authorization was granted. With three ERTs and
two SRTs for GD now available, GOS, as a disease-speciﬁc registry,
provides a platform for collecting information for the evidence-
based management of GD.
In this report, information on GD-speciﬁc treatment patterns was
gathered from 10 countries, including three countries with 65 orPlease cite this article as: P. Deegan, et al., Blood Cells Mol. Diseases (2016more treated patients (Israel, United States, and United Kingdom).
The treatment patterns seen in these three highest-enrolling coun-
tries reﬂect the historical availability (including the imiglucerase
shortage) andmarketing authorization dates of available GD-speciﬁc
treatments.
The GOS population at the time of analysis comprised many more
treated patients than untreated patients. Notably, the United States
and United Kingdom had low numbers of untreated patients compared
with treated patients. Conversely, over one-third of GOSpatients in Isra-
el were untreated.
There were strong differences in GBA1 genotype representation be-
tween treated and untreated patients. More than three-quarters of un-
treated patients were homozygous for the N370S mutation, a
genotype generally (but not always) associated with late symptom
onset andmild hematological and visceral disease [20]. TheN370S allele
has a particularly high frequency among people of Ashkenazi Jewish
ethnicity and N80% of the N370S/N370S patients in GOS are located in
Israel, which may explain Israel's high number of untreated patients
compared with other countries in GOS [21]. Nearly all patients hetero-
zygous for N370S and a more severe mutation (N370S/L444P or
N370S/84GG) were receiving treatment; these genotypes usually result
in early-onset disease that is more severe than that associated with
N370S/N370S [22].
Among patients on treatment at the time of analysis, N95% were re-
ceiving ERT, with velaglucerase alfa and imiglucerase accounting for the
majority of treatments received. Most patients on taliglucerase alfa
were located in Israel, likely reﬂecting its lack of marketing authoriza-
tion in Europe and Israel's participation in its clinical development pro-
gram. There are relatively few patients in GOS receiving eliglustat,
which may be due to it being the newest of the GD-speciﬁc treatments
and because it does not yet have marketing authorization in Israel,
where most GOS patients are located. The United States was the only
country to report the use of all available GD-speciﬁc treatments, proba-
bly because it has a high number of participating sites compared with
other countries in GOS and therefore may include a range of local pre-
scribing practices.), http://dx.doi.org/10.1016/j.bcmd.2016.10.014
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Fig. 3. GBA1 genotypes of patients in the three highest-enrolling countries. Many patients with the N370S/N370S genotype are asymptomatic or have mild GDmanifestations. Israel had
the highest proportion of N370S/N370S patients (227/398 [58.4%], compared with 46/176 [26.1%] in the United States and 3/51 [5.9%] in the United Kingdom), whichmay partly explain
the high numbers of patients in Israel whowere untreated or receiving low-dose treatment (b20 U/kg every other week) compared with the United States and the United Kingdom. GD,
Gaucher disease.
5P. Deegan et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxOur analysis of GOS patients treated with velaglucerase alfa showed
that most received the drug at 60 U/kg every other week, which is the
dose recommended in the prescribing information for treatment-
naïve patients with type 1 GD. Dosing differed between age groups;
b20 U/kg was the dose most commonly received by patients
≥18 years of age, whereas b20 U/kg was almost never administered to
patients b18 years of age, who most commonly received treatment at
60 U/kg.
Clear differences in every-other-week dosing between
the three highest-enrolling countries were observed. In Israel,
b20 U/kg was the most common dose used, compared with 20 to
b40 U/kg in the United Kingdom and 60 U/kg in the United States.
In Israel, administration of low doses of ERT (equivalent toPlease cite this article as: P. Deegan, et al., Blood Cells Mol. Diseases (201615 U/kg every other week) was initially chosen to reduce costs,
but continues to be used following studies suggesting that low-
dose therapy does not compromise clinical beneﬁt [19,23–25].
The policy for prescribing low-dose therapy in Israel is strongly
reﬂected in GOS data on velaglucerase alfa treatment regimens,
and may also be related to the high number of N370S/N370S pa-
tients (who may have mild disease) in Israel. In the United States,
support of an every-other-week dose of 60 U/kg by insurance
companies may account for why this treatment regimen is most
commonly used.
An observational study with alglucerase and imiglucerase has
shown an incremental dose-response relationship for hemato-
logical and visceral parameters across a range of typically used), http://dx.doi.org/10.1016/j.bcmd.2016.10.014
1N
um
be
r o
f p
at
ie
nt
s
Israel
(n = 273)
US
(n = 163)
UK
(n = 65)
Brazil
(n = 32)
Paraguay
(n = 14)
France
(n = 11)
Italy
(n = 6)
Spain
(n = 4)
Russia
(n = 3)
Argentina
(n = 2)
0
50
100
150
200
250
300
1
(0.2%)12(2.1%)
10
(1.7%)
1
5
Currently treated patients (n = 573)
316
(55.1%)
184
(32.1%)
81
158
90
37
1
11 31 2 3 2
34
46
1
27
23 14
10
11
1
6
2
2
50
(8.7%)
Velaglucerase alfa
Imiglucerase
Taliglucerase
Eliglustat
Miglustat
Alglucerase
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6 P. Deegan et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxxdoses [26]. However, the optimal ERT dosing strategy is an unre-
solved issue in GD [24]. Further examination of outcomes data
from GOS and their relationship with dose may help address
some of the unresolved questions related to optimal treatment
strategies.
A number of limitations of these GOS data are noted. Participa-
tion in the registry is voluntary (at the discretion of the patient
and the physician), which may result in selection bias, particularly
in the reporting of treated patients over untreated patients. Fur-
thermore, because GOS is sponsored by one company, data from
velaglucerase alfa-treated patients may be reported ahead of
those receiving other GD-speciﬁc treatments, leading to a greater
percentage of patients in GOS receiving velaglucerase alfa com-
pared with imiglucerase (which is the most widely used ERT
worldwide). While physicians are encouraged to enter information
for all their GD patients regardless of the treatment they receive,
there are other disease- and treatment-speciﬁc registries for GD,
and some sites may not be able to enroll all patients into all regis-
tries for which they are eligible. With nearly half of GOS patients
being located in Israel, results could be biased toward treatment
approaches used in Israel, where patients may have milder disease
and many are untreated. Furthermore, data reported from sites
participating in GOS may not be representative of their country's
GD patient population.5. Conclusions
These real-world data from GOS help to describe the long-term na-
ture of GD treatment. In GOS patients, ERT accounts for over 95% of
treatment received and most patients have been treated for N5 years.
Although most patients received treatment with a single drug, changes
from one ERT to another accounted for the majority of treatment
switches. Overall, our data indicate a range of approaches toward GD
management globally, which can be inﬂuenced by a number of
interacting factors including drug availability, treatment cost, local pre-
scribing practices, and disease severity. Further analyses from GOS can
help examine the impact of these treatment patterns on real-world
outcomes.Please cite this article as: P. Deegan, et al., Blood Cells Mol. Diseases (2016Authorship contributions
PD, DF-S, PG, HL, and AZ are investigators involved in GOS. ZP is the
GOSmedicalmonitor. All authors contributed to the development of the
manuscript, critically reviewed the manuscript during development,
and approved the ﬁnal draft prior to submission.
Conﬂicts of interest disclosures
PD receives consulting fees from Genzyme, Shire, Amicus, and
Alexion; has participated in clinical trials sponsored by Genzyme, Ami-
cus, Protalix, and Shire; and has conducted research supported by
Genzyme and Shire. DF-S receives consulting fees from Shire. PG re-
ceives consulting fees fromGenzyme, Shire, and Pﬁzer; has participated
in clinical trials sponsored by Genzyme, Amicus, Protalix, and Shire; and
has conducted research supported by Genzyme, Shire, and Actelion. HL
is a member of the advisory board or similar committee of Shire, re-
ceives consulting fees fromGenzyme/Sanoﬁ and Pﬁzer; has participated
in clinical trials sponsored by Amicus, Biomarin, GlaxoSmithKline,
Genzyme/Sanoﬁ, Shire, Pﬁzer, and Ultragenyx; has participated in clin-
ical studies using products manufactured by Amicus, Biomarin,
Genzyme/Sanoﬁ, Pﬁzer, Shire, and Ultragenyx; and conducts research
supported by Genzyme/Sanoﬁ. ZP is an employee of Shire. AZ receives
honoraria fromShire, Genzyme/Sanoﬁ, and Pﬁzer, and his institution re-
ceives support fromGenzyme, Shire, and Pﬁzer for participation in their
respective registries.
Acknowledgements
GOS is funded by Shire Human Genetic Therapies, Inc. Under the di-
rection of the authors, Julia Cope, PhD, employee of Excel Scientiﬁc So-
lutions, provided writing assistance for this publication. Editorial
assistance in formatting, proofreading, copy editing, and fact-checking
was also provided by Excel Scientiﬁc Solutions. Svetlana Bizjajeva,
PhD, from Shire International GmbH provided statistical support and
also reviewed themanuscript for scientiﬁc accuracy. Shire International
GmbHprovided funding to Excel Scientiﬁc Solutions for support inwrit-
ing and editing this manuscript.), http://dx.doi.org/10.1016/j.bcmd.2016.10.014
0 20 40
>60 U/kg
(n = 28)
60 U/kg
(n = 138)
40 to <60 U/kg
(n = 100)
20 to <40 U/kg
(n = 109)
<20 U/kg
(n = 117)
0 20 40 60 80 100 120
Ve
la
gl
uc
er
as
e 
al
fa
 d
os
e
Number of patients
Patients <18 years of age
n = 55; entries = 86
Patients ≥18 years of age
n = 322; entries = 406
Every other week Weekly Every 3 weeks Monthly Unknown/other
111
6
47
23
35
19 19
50
44
2
70
4 4
18
0
20
40
60
80
100
120B
A
Israel
(225 dose entries)
UK
(54 dose entries)
US
(173 dose entries)
N
um
be
r o
f d
os
e 
en
tri
es
<20 U/kg
20 to <40 U/kg
40 to <60 U/kg
60 U/kg
>60 U/kg
Fig. 5.Dosing inpatientswho received velaglucerase alfa at any time (n=377). A)Dose and frequency of velaglucerase alfa received by age group. Treatmentwas administered at a variety
of doses and frequencies, but most commonly at 60 U/kg every other week (134/492 dose entries, 27.2%). B) Velaglucerase alfa dosing in the three highest-enrolling countries in GOS. In
Israel, most patients received velaglucerase alfa at b20U/kg, while the dosemost commonly received in the United Kingdomwas 20 to b40U/kg and in the United Stateswas 60 U/kg. For
dose entrieswith a frequency of administration reported, treatmentwas administered every otherweek for all entries reported from Israel (223/223, 100%), 52/54 (96.3%) entries from the
United Kingdom, and 159/170 (93.5%) entries from the United States. GOS, Gaucher Outcome Survey.
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